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Background: Rheumatoid arthritis (RA) is a debilitating and painful disease leading to increased morbidity and
mortality and novel therapeutic approaches are needed. The purpose of this study was to elucidate if mesenchymal
stem cells (MSCs) injected in the joints of mice with arthritis are therapeutic, reducing joint swelling and cartilage
destruction.
Methods: Murine mesenchymal stem cells (mMSCs) were isolated from bone marrow of C57Bl/6 mice and
expanded in culture. Cells were tested for immunophenotype and their ability to form colonies and to differentiate
into chondrocytes, osteocytes and adipocytes. Antigen-induced arthritis (AIA) was induced by intra-articular injection of
methylated bovine serum albumin into the knee joints of preimmunized C57Bl/6 mice. After one day, when peak
swelling occurs, 500,000 mMSCs labelled with red fluorescent cell tracker CM-DiI were injected intra-articularly in
the right knee joint. Left knee joints were treated as controls by receiving PBS injections. Differences between
groups were calculated by Mann Whitney U test or unpaired t tests using GraphPad Prism software version 5.
Results: Knee joint diameter (swelling) was measured as a clinical indication of joint inflammation and this
parameter was significantly less in MSC-treated mice compared to control-treated animals 48 hours after arthritis
induction. This difference continued for ~7 days. CM-DiI-labelled MSCs were clearly visualised in the lining and
sublining layers of synovium, in the region of the patella and femoral and tibial surfaces. By day 3, parameters
indicative of disease severity, including cartilage depletion, inflammatory exudate and arthritic index were shown
to be significantly reduced in MSC-treated animals. This difference continued for 7 days and was further confirmed
by histological analysis. The serum concentration of tumour necrosis factor α was significantly decreased following
MSC administration.
Conclusions: Our results reveal that MSCs injected in the joints of mice with AIA are therapeutic, reducing
inflammation, joint swelling and cartilage destruction. These cells also integrate into the synovium in AIA.
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Rheumatoid arthritis (RA) is a debilitating and painful
disease leading to increased morbidity and mortality and
novel therapeutic approaches are needed. Recent advances
using biologic drugs, such as anti-TNF, have made a sig-
nificant impact on the treatment of RA patients although
many patients do not respond and 50% discontinue the
drug after 2 years [1]. For that reason, it is vital to develop
a new and more effective therapy for RA.
Mesenchymal stem cells (MSCs) show therapeutic
potential in pre-clinical models of inflammatory diseases
and in some clinical trials in patients with Crohn’s disease,
diabetes, GVHD and myocardial infarction [1]. Recently,
the first human trial using umbilical cord mesenchymal
stem cells (UC-MSCs) was published for RA and the re-
sults confirmed the safety and efficacy of UC-MSC infu-
sion in active RA patients [2]. MSCs are an ideal
candidate cell type for tissue engineering and cell therapy
to repair damaged structures in various arthritic condi-
tions. MSCs possess anti-inflammatory and immuno-
suppressive properties modulated by the secretion of
biologically active molecules [3] and since RA is a chronic
inflammatory autoimmune disease involving tissue de-
struction, the anti-inflammatory and regenerative func-
tions of MSCs could be exploited as a therapy [4]. MSCs
have been given intravenously or intraperitonealy in ani-
mal models of RA and lead to different therapeutic effects,
varying from significant improvement to no effect so over-
all the results remain inconclusive [5]. The reason for this
may be the route of administration. A number of studies
used intravenous or intraperitoneal administration and the
MSCs were not reported to migrate into the joints to exert
their effects, but have been located in the spleen [3,4].
Intra-articular administration of MSCs may be more bene-
ficial than the intravenous/intraperitoneal route, applying
them directly to the affected tissues.
Here, we investigated whether intra-articular injected
MSCs are therapeutic, reducing joint swelling and cartil-
age destruction in murine antigen-induced arthritis (AIA).
The characteristics of this model are as follows [6-9]: pre-
immunisation induces humoral and cell-mediated immun-
ity; leukocyte migration occurs into the joint, including
neutrophils, lymphocytes, plasma cells and macrophages;
it is a uniarthritis with controlled onset; pannus formation
occurs resulting in erosive changes of cartilage and bone;
it is antigen-specific with local hyper-reactivity and anti-
gen retention in cartilage; chronicity can be achieved by
repeated flares.
Methods
Animals
Experiments were undertaken in 7- to 8-wk-old C57Bl/6
male mice. Procedures were performed in accordance with
Home Office-approved project licence PPL 40/3594.Induction of murine AIA
Murine AIA was induced as described [6]. Briefly, mice
were immunised subcutaneously with 1 mg/ml of meth-
ylated BSA (mBSA) emulsified with an equal volume of
Freund’s complete adjuvant and injected intraperitonealy
with 100 μl heat-inactivated Bordetella pertussis toxin
(all reagents were from Sigma-Aldrich). The immune re-
sponse was boosted 1 week later. Twenty-one days after
the initial immunisation, murine AIA was induced by
intra-articular injection of 10 mg/ml mBSA in the right
knee (stifle) joint. For a control, the same volume of PBS
was injected into the left knee joint. Animals were
inspected daily for arthritis development by measuring
knee joint diameters using a digital micrometer (Kroeplin
GmbH). The difference in joint diameter between the
arthritic (right) and non-arthritic control (left) in each ani-
mal gave a quantitative measure of swelling (in mm).
Cells
Murine MSCs (mMSCs) were isolated from C57Bl/6
mice (n = 5) as previously described [10]. Briefly, bone
marrow cells were collected by flushing them out of fe-
murs and tibiae and cells plated out in cell isolation
media (CIM) (RPMI-1640) (Gibco,UK) with 9% fetal
bovine serum (Gibco,UK), 9% horse serum (Gibco, UK)
and 1% penicillin-streptomycin at 37°C in 5% CO2. After
24 hours, nonadherent cells were removed and 4 weeks
later, cells were re-plated at 100 cells per cm2 in complete
expansion media (CEM) (Iscove Modified Dulbecco Medium
(IMDM)) (Gibco, UK) supplemented with 9% fetal bovine
serum (Gibco, UK), 9% horse serum (Gibco, UK) and 1%
penicillin-streptomycin for MSC expansion. Cells were ex-
amined for their ability to differentiate into chondrocytes
(using pellet cultures), osteocytes and adipocytes, as de-
scribed [10].
For the colony-forming unit assay 100 cells at passage
3 were plated in triplicate on 58 cm2 plates in CEM as
described in [10]. Cells were incubated for 14 days in
CEM, and stained with 3% crystal violet in methanol at
room temperature for 20 minutes. All visible colonies
were counted. Passage 3 cells were tested for immuno-
phenotype with the following antibodies: anti-mouse
Ly-6A (Sca-1)PE, anti-human/mouse CD44 PE, anti-
mouse CD11b PE, anti-mouse CD45 PE and anti-mouse
CD31 PE (all from eBioscience) using flow cytometry. Data
were collected and displayed in dot plot and histogram
format using CellQuestPro software (Becton Dickinson,
Oxford, UK). More than 95% of mMSCs were positive for
Sca-1 (murine MSC marker) and CD44 (mesenchymal cell
marker) cell surface markers and were less than 3% posi-
tive for CD11b (macrophage and monocyte marker),
CD45 (leukocyte marker) and CD31 (endothelial cell
marker). Propidium iodide staining was included in the
immunophenotyping to evaluate the viability of the cells.
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A stock solution of the red fluorescent cell tracker CM-
DiI (Molecular Probes, UK) was prepared in dimethyl
sulfoxide (DMSO) at concentration of 1 mg/ml. MSCs
were trypsinized, washed with phosphate-buffered saline
(PBS), and incubated in the working solution of CM-DiI
(2.5 μl of stock per 1 ml of PBS) for 5 minutes at 37°C,
and then for additional 15 minutes at 4°C, in the dark.
Unincorporated dye was then removed by centrifugation
at 300 g for 5 minutes and 2 washes in PBS. Cells were
resuspended in serum free IMDM and maintained at 4°
until injection.Intra-articular injection of MSCs
After one day post arthritis induction, when peak swelling
occurs, 10 μl of serum free IMDM, containing 500,000
MSCs labelled with cell tracker CM-DiI were injected
intra-articularly (0.5 ml monoject (29 G) insulin syringe,
BD Micro-Fine, Franklyn Lakes, USA) through the patellar
ligament into the right knee joint. Stretching of the hind-
leg facilitated the intra-articular injection. Control animals
were injected with 10 μl of serum free IMDM. Joint diam-
eters were measured at days 1, 2, 3, 5, 7, 14, 21 and 28. At
the end of the experiments, animals were killed and joints
were collected for histology. Experiments were performed
independently, twice, and all measures were made to re-
duce the number of used animals (n = 6 animals/per time
point).Histological assessment
Animals were sacrificed at the indicated times after induc-
tion of arthritis (at days 3, 7, 14, 21 and 28; n = 6 animals/
per time point). Joints were fixed in neutral buffered for-
mal saline, and decalcified with formic acid at 4°C before
embedding in paraffin. Mid-sagittal serial sections (5 μm
thickness) were cut and stained with haematoxylin and
eosin (H&E). For detection of CM-DiI-labelled MSCs, sec-
tions were rehydrated through a xylene and alcohol,
stained with fluorescent dye DAPI (Sigma-Aldrich, UK),
mounted in Hydromount (National Diagnostics, UK) and
examined by fluorescence microscopy. Two independent
observers blinded to the experimental groups scored H&E
sections. Synovial hyperplasia, cellular exudate and cartil-
age depletion were scored from 0 (normal) to 3 (severe);
synovial infiltrate was scored from 0 to 5 [6]. Cartilage
damage was scored on serial toluidine blue stained sec-
tions. All parameters were subsequently summed to give
an arthritis index (mean ± SEM).
Endothelial cells in the joint synovia were identified by
immunofluorescence with rabbit anti-von Willebrand
factor (1:100; Dako, Ely, UK) followed by goat anti-rabbit
Alexa 488 second antibody (1:400; Life Technologies,
Paisley, UK).TNFα assay
Serum concentration of TNFα was measured using a
mouse TNFα ELISA Ready-SET-Go! Kit (eBioscience)
according to the manufacturer’s instructions.
Statistical analysis
Differences between groups were compared by Mann
Whitney U or unpaired t tests, using GraphPad Prism
software version 5. P values less than 0.05 being deemed
as significant.
Results
Characterisation of murine bone marrow MSCs
mMSCs were successfully differentiated towards adi-
pogenic, osteogenic and chondrogenic lineages after
21 days in culture with relevant differentiation media
(Figure 1A-C). Adipogenic differentiation was verified
by the presence of lipid droplets stained positive with
oil red O (Figure 1A), the osteogenic differentiation
was detected by alkaline phosphatase (ALP) staining
(Figure 1B) and chondrogenesis was confirmed by for-
mation of dark blue/purple proteoglycan-producing
pellets (Figure 1C). Colony-forming units assay was
used to assess the proliferative capacity of the cells
being expanded in culture, and the results showed that
passage 3 cells retained the high proliferation rate in
culture (Figure 1D).
Flow cytometry analysis showed that isolated and cul-
tured mMSCs were negative for hematopoietic markers
CD11b and CD45, the endothelial cell marker CD31
(PECAM), and positive for the mesenchymal markers
CD44 and Sca-1 (Figure 1E). Propidium iodide staining
indicated a cell viability >96%.
Decreased severity of AIA following treatment with
murine MSCs
AIA is model of inflammatory arthritis with many histo-
pathological and clinical similarities to RA [6-9]. In
order to investigate the therapeutic effects of mMSCs
we used AIA which was induced in the right knee joints
of C57Bl/6 mice (t = 0). After one day, when peak swell-
ing occurs, the knee joints were injected with mMSCs.
Knee joint diameters (swelling) were measured as a clin-
ical indication of joint inflammation and this parameter
(mean ± SEM in mm) was significantly less in MSC-
treated mice compared to control-treated animals 2 days
after arthritis induction (0.98 ± 0.06 mm versus 1.27 ±
0.06 mm; p = 0.0009) (Figure 2A). This difference contin-
ued for ~7 days post intra-articular mBSA administration
(0.34 ± 0.06 mm versus 0.74 ± 0.09mm; p = 0.0009). At
days 14 and 21 there were no significant differences in
swelling between MSC-treated and non-treated animals.
Histologically AIA was characterised by synovial
hyperplasia of the synovial lining layer, infiltration of
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Figure 1 In vitro characterisation of murine MSCs (mMSCs). Passage 3 mMSCs underwent successful differentiation down adipogenic (A), osteogenic
(B) and chrondrogenic (C) lineages after 21 days in appropriate differentiation media. D) Representative colony-forming unit analysis.
E) Immunophenotypic profile of passage 3 mMSCs are negative for haematopoietic markers CD11b and CD45, endothelial marker CD31 and positive
for mesenchymal markers CD44 and Sca-1. The solid peak is corresponding isotype control. Scale bars = 100 μm in A and B, 200 μm in C.
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joint cavity, and loss of proteoglycans from the articular
cartilage, as observed in haematoxylin/eosin and tolui-
dine blue stained sections (Figure 2B, D and E). These
changes did not occur in contralateral knee joints which
were injected with PBS instead of mBSA and appeared
histologically normal. The inflammation and cartilage
degradation appeared less severe in MSC-treated mice
compared to control treated (Figure 2B-F). In order to
quantitate these changes, the parameters were scored as
a measure of disease severity and differences between
MSC-treated and non-treated mice were evident (Table 1).
In MSC-treated mice at day 3 there was a significant
reduction of amount of exudates in the joint cavity
which contained leukocytes including neutrophils (p =
0.0004), cartilage depletion (p = 0.0003) and arthritisindex representing overall disease severity (p = 0.0009)
(Table 1, Figure 2B-F). At day 7 post intra-articular in-
jection of mBSA, there were still significant differences
between MSC-treated and non-treated mice for exud-
ate (p = 0.024), cartilage depletion (p = 0.035), synovial
hyperplasia (p = 0.01) and arthritis index (p = 0.013). At
day 14, all parameters were reduced in the presence of
MSCs although these only approached significance (eg
p = 0.09 for cartilage depletion) (Table 1). At day 28 post
intra-articular injection of mBSA, there were no signifi-
cant differences between MSC-treated and control-treated
animals for all parameters.
Serum levels of TNFα were lower in the MSC-treated
group with AIA compared to the non-treated group at day
3 (p = 0.024), day 7 (p = 0.001) and day 14 (p = 0.008)
(Figure 3).
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Figure 2 (See legend on next page.)
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Figure 2 The effects of intra-articular injection of murine MSCs (mMSCs) into knee joints of mice with antigen-induced arthritis.
Arthritis was induced by intra-articular injection of methylated BSA in the right knee (stifle) joint (t = 0 in A). For a control, PBS was injected into
the left knee joint. Murine MSCs were isolated from bone marrow and expanded in culture. 500,000 mMSCs in serum free medium were injected
at the peak of joint swelling (after 1 day) into the knee joints of mice with arthritis. Injection of serum free medium alone was control. (A) Reduced joint
swelling in the presence of mMSCs. Joint diameters were measured as an index of swelling (joint inflammation). Data are means ± SEM for right knee
after subtraction of left knee control; n = 6 mice with MSCs and control without MSCs. *p < 0.05, ***p < 0.001 compared with corresponding time point.
(B-F) Histology of joints in mouse antigen-induced arthritis 3 days after induction. (B) Arthritic knee joint with marked leukocyte exudates in the joint
space (*). (C) is the same as B except MSCs have been injected. Note the lack of exudates. (D) detail of exudate in the joint cavity in the absence of
MSCs comprising leukocytes, particularly neutrophils (arrows show examples). (E) arthritic knee joint with loss of proteoglycan staining in the surface
regions of tibial and femoral articular cartilage (arrow). F is the same as E except the joint was injected with mMSCs and there is less cartilage
degradation. B, C and D were stained with haematoxylin and eosin and E and F with toluidine blue. Scale bar =500 μm in B and C, 20 μm in D
and 200 μm in E and F.
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of knee joints
3, 7, 14 and 28 days after arthritis induction CM-DiI-
labelled MSCs were clearly visualised in the lining and
sublining layers of the synovium, in the region of the pa-
tella, and femoral and tibial surfaces (Figure 4A and D).
Figure 4E illustrates absence of MSC-endothelial cell co-
localisation in the synovium of injected joints. At all
time points there was no localisation of labelled MSCs
in other joint tissues such as articular and meniscal car-
tilage. To further assess whether injected MSCs could
migrate to some distant organs or not, we tried to detect
CM-DiI-labelled red-fluorescent MSCs by immunofluor-
escence in contralateral joints and in lungs, spleens and
livers of mice at the end of the experiments. We were
unable to identify any red-fluorescent cells in these or-
gans at different time points during the experiment
(Figure 4F-I).
Discussion
In this study, we examined a therapeutic strategy for
arthritis using a single intra-articular injection of MSCs.
We found that these cells are therapeutic, reducing the
severity of AIA in mice. An injection of 500,000 MSC
given at the peak of joint swelling was enough to prevent
the occurrence of severe cartilage damage, and reduce
joint inflammation and exudate in the joint cavity. StudiesTable 1 Joint inflammation and cartilage damage on day 3, 7
histological scoring
Species Days Hyperplasia Synovial infiltrate
Control animals 3 1.75 ± 0.29 3.56 ± 0.40
7 2.43 ± 0.23 3.93 ± 0.39
14 1.67 ± 0.67 1.67 ± 1.20
MSC treated animals 3 1.70 ± 0.17 2.83 ± 0.25
7 1.19 ± 0.28* 2.69 ± 0.43
14 1.00 ± 0.00 (p = 0.39) 1.00 ± 0.41 (p = 0.58
Synovial hyperplasia of the lining layer, synovial infiltration of the sublining by leuk
cartilage were observed in haematoxylin/eosin and toluidine blue stained sections.
(hyperplasia, exudate and cartilage depletion) or 0 to 5 (infiltrate). The arthritis inde
compared to control animals at the same point, using unpaired t test. n = 6 mice.of MSCs as a cellular therapy for animal models of RA
exhibit contradictory results [5]. Experimental protocols
differed between all of these studies, which may, in part,
explain discrepancies in results.Djouad et al, Mao et al
and Choi et al used intravenous but González et al. used
intraperitoneal administration and the MSCs were not
reported to migrate into the joints to exert their effects,
but have been located in the spleen [5,11-13]. Further-
more intravenously injected MSCs are known to be-
come lodged in the lungs which could further hamper
their therapeutic effect [14]. Our data suggest that intra-
articular administration of MSCs may be more beneficial
than the intravenous/intraperitoneal route, applying them
directly to the affected tissues. The homing of systemically
injected MSCs in the AIA model has not been studied and
will be of the interest to compare with the results of intra-
articular administration used in the present study and to
compare with other models such as systemic injections in
collagen-induced arthritis. Our findings indicate that joint
swelling in arthritis as a clinical indication of joint inflam-
mation is reduced in the presence of administered MSCs
and these cells migrate into the inflamed synovium. Fur-
thermore, MSCs reduce the amount of exudates in the
joint cavity. Joint swelling is common with different types
of arthritis and is caused by oedema due to the endothelial
cells of blood vessels becoming leaky in the inflamed syno-
vium [15]. We hypothesise that soluble factors producedand 14 of antigen-induced arthritis as assessed by
Exudate Cartilage depletion Arthritis index
2.78 ± 0.15 1.78 ± 0.33 9.89 ± 0.88
2.14 ± 0.46 1.71 ± 0.52 10.2 ± 1.46
1.17 ± 0.92 1.50 ± 0.87 6.00 ± 3.61
1.13 ± 0.32*** 0.33 ± 0.14*** 5.96 ± 0.57***
0.75 ± 0.31* 0.44 ± 0.29* 5.06 ± 1.09*
) 0.00 ± 0.00 (p = 0.19) 0.00 ± 0.00 (p = 0.09) 2.00 ± 0.41 (p = 0.25)
ocytes, exudate in the joint cavity, and loss of proteoglycan from the articular
Sections were scored blind by two independent observers from 0 to 3
x is the sum of all observations. *p < 0.05; and ***p < 0.001 of the parameter
3 7 14
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non-treated group
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Figure 3 Serum concentration of TNFα at the indicated time
points (day 3, 7 and 14), analysed by enzyme-linked
immunosorbent assay. Data are means ± SEM; n = 6 mice with
MSCs and control without MSCs. *p < 0.05, **p < 0.01.
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synovial endothelial cells, although further studies are re-
quired in this regard. Direct MSC-endothelial cell contact
is most likely not responsible since these cells did not
colocalise (Figure 4E). In this connection, in vitro and
in vivo studies with pulmonary endothelial cells reveal that
MSCs and conditioned media from these cells inhibit
endothelial cell permeability and lung oedema by preserv-
ing adherent junctions (VE-cadherin and β-catenin) [16].
Recent studies show that complexes of alarmins S100A8
and S100A9, which are major products of neutrophils and
macrophages [17], bind to endothelial cells via specific
interaction with heparan sulphate proteoglycans, inducing
inflammatory responses in endothelial cells and increasing
the endothelial permeability [18]. It is currently unknown
if mMSCs and alarmins effect permeability of the synovial
endothelial cells.
Histological analysis of joint sections was used to de-
termine the nature of cells in exudate within the joint
space. Leukocytes, and in particular neutrophils, were
identified by their nuclear morphology and were broadly
distributed throughout joint exudate in control-treated
mice. There was a significant reduction of amount of ex-
udates, comprising leukocytes in the joint cavity in
MSC-treated mice at days 3 and 7 after arthritis induc-
tion. Neutrophils have been considered as important
cells in the development of inflammatory joint disease,
as supported by several studies involving experimental
models of arthritis [19]. Neutrophils are found in high
numbers within the human rheumatoid joint, especially
in the joint fluid. Here they have a significant potential
to directly inflict damage to tissue, bone and cartilage via
the secretion of proteases and toxic oxygen metabolites, as
well as driving inflammation through antigen presentation
and secretion of cytokines, chemokines, prostaglandins
and leucotrienes [20]. Neutrophil depleted mice are com-
pletely resistant to the inflammatory effects of arthrito-
genic serum from K/BxN mice [19]. In the present study
an intra-articular injection of MSCs given at the peak ofjoint swelling reduces the accumulation of leukocytes in
the joint fluid in AIA which may be related to the reduced
joint damage in terms of cartilage depletion. It is possible
that soluble anti-inflammatory factors produced by MSCs
influence leukocyte accumulation in the joint fluid during
inflammation in AIA. In the synovium there was also a re-
duction in leukocyte infiltration but this did not reach
statistical significance.
Cartilage damage was scored on serial toluidine blue–
stained sections based upon proteoglycan loss in articular
cartilage. Healthy cartilage shows a dark blue stain and a
loss of cartilage proteoglycans is indicated by cartilage
destaining [21].
We directly compared the extent of cartilage damage in
control and MSC-injected sections by semi-quantitative
histological scoring (Table 1) and cartilage depletion was
scored from 0 (normal) to 3 (severe).
Our results showed inhibition of proteoglycan loss, a
marker of early cartilage destruction, by local MSC
treatment. Breakdown of the cartilage matrix is one of
the features of RA. Aggrecan can be cleaved by both
matrix metalloproteinases (MMPs) and a disintegrin and
metalloproteinase with a thrombospondin type 1 motif
(ADAMTS) at different sites. Formation of the NITEGE
(ADAMTS-cleaved) and DIPEN (MMP-cleaved) aggrecan
neoepitopes and their detection with neoepitope anti-
bodies can provide information about which enzyme is
the major one that degrades aggrecan in mouse cartilage
and has set a target for the development of new drugs
designed to inhibit cartilage destruction in RA [22].
Early cartilage destruction in AIA is characterised by
loss of aggrecan and the ADAMTS family members are
thought to be involved in mediating this loss [18,23].
ADAMTS-5 is of special interest since only lack of the
Adamts-5 gene prevents cartilage damage in a mouse
model of arthritis [24]. It is possible that factors re-
leased by MSCs influence the activity or expression of
ADAMTS enzymes resulting in less aggrecan degrad-
ation. It has been shown in experimental osteoarthritis
model that stem cell treatment strongly inhibited ex-
pression of neo-epitopes (NITEGE), suggesting sup-
pression of ADAMTS activity [17]. Another possibility
is that MSCs are directly differentiating into chondro-
cytes leading to less cartilage destruction. However,
this is unlikely as injection of fluorescently labelled
MSCs did not localise to cartilage but to the inflamed
synovium (Figure 4A and 4D).
TNFα is a cytokine involved in inflammation and tissue
degradation in RA. The finding that administration of
MSCs results in reduced levels of TNFα in the circulation
may be related to their anti-inflammatory effects, in terms
of reducing oedema, swelling and leukocyte accumulation,
and cartilage protective effects namely inhibiting proteo-
glycan degradation.
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Figure 4 MSCs injected into the joint localise to the synovium. 500,000 CM-DiI-labelled red-fluorescent mouse MSC were injected intra-articularly
into the knee joint spaces of mice with antigen-induced arthritis. (A) low magnification image of a mouse joint 2 days after MSC injection, the arrows
indicate MSCs (red) localising to the synovium. (B) joint of control treated mouse 2 days after MSC injection, no red fluorescence, DAPI blue. (C) low
magnification H&E stained image of a mouse joint 2 days after MSC injection (same joint as A), the arrows indicate regions of MSC localisation
(corresponding to A). (D) higher magnification showing MSCs localising to the lining of synovium (C-cartilage; L-lining layer of the synovium;
S-sublining layer of the synovium). DAPI stain cell nuclei. (E) sections were treated with rabbit anti- von-Willebrand factor antibodies followed by goat
anti-rabbit Alexa 488 to identify endothelial cells (arrows) in MSC-injected joints. Absence of red fluorescence in F- contra-later joint, G- lungs, H-spleen
and I-liver. Scale bar 500 μm in A, B, C; 50 μm in D and E; and 200 μm in F-I.
Kehoe et al. Journal of Translational Medicine 2014, 12:157 Page 8 of 10
http://www.translational-medicine.com/content/12/1/157
Kehoe et al. Journal of Translational Medicine 2014, 12:157 Page 9 of 10
http://www.translational-medicine.com/content/12/1/157Several groups demonstrated therapeutic effects of
intra-articular injections of MSCs in experimental osteo-
arthritis models [17,25-27]. These studies showed anti-
inflammatory and reparative effects on cartilage using
both bone marrow-derived and adipose-derived stem cells.
In addition, intra-articularly injected adipose-derived stem
cells were found to home to the subintimal synovial lining
layer in mice [17]. The current study in an RA model is in
general agreement with these osteoarthritis models.
Conclusion
Our data demonstrate that an intra-articular injection of
MSCs into the knee joints of mice with AIA ameliorates
the severity of disease, causing reduced swelling, exudates
in the joint fluid and cartilage damage. These MSCs home
to the synovium.
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